OraSure Secures $7.5M Contract With $11M Potential for Marburg Virus Rapid Test Development
OraSure Secures $7.5M Contract With $11M Potential for Marburg Virus Rapid Test Development
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
OraSure Technologies, Inc. (納斯達克:OSUR)是一家在現場和家庭診斷測試及樣本管理解決方案方面的領導者，今天宣佈通過快速反應夥伴關係工具（RRPV）獲得了一項獎項，用於開發馬爾堡病毒病（MVD）快速抗原檢測。RRPV是一個由生物醫藥先進研究與發展局（BARDA）資助的財團，該局是美國衛生與公共服務部（HHS）戰略準備與響應管理局（ASPR）的一部分。
The initial contract award, valued at approximately $7.5 million over multiple years in the base period with potential value up to $11 million, funds the development to achieve U.S. Food and Drug Administration (FDA) 510(k) clearance of a single-use lateral flow immunoassay intended for the qualitative detection of antigens from viruses within the Marburg virus genus. We expect that the proposed test will be intended for use with specimens from individuals with epidemiological risk factors who have signs or symptoms of MVD or from recently deceased individuals with epidemiological risk factors who are suspected to have died of MVD.
初始合同的授予價值約爲750萬美元，涵蓋多個年度的基礎期，潛在價值可達1100萬美元，資金用於達到美國食品和藥物管理局（FDA）510(k)的批准，目標是開發一種一次性側流免疫測定法，用於定性檢測來自馬爾堡病毒屬的病毒的抗原。我們預計，擬議的測試將用於從具有流行病學風險因素的個體中提取樣本，這些個體有MVD的跡象或症狀，或者是來自近期去世的具有流行病學風險因素，懷疑因MVD而死亡的個體。
